Meta-analysis of anti-thrombotic options after open revascularisation for PAD, by Luke Davies.

Meta-analysis of anti-thrombotic options after open revascularisation for PAD.

Luke Davies

Medical student

From Bristol

Lists Hinchclifee and Graeme Ambler

PAD affects 230 mi wordlwide

5 yr mortlality of CLTI Rx is 50%

1 yr reintervention rate after bypass stated as 18%

Mentions BEST CLI trial - the study did not specify post revasc Rx BMT

Outcomes of study

primary efficacy outcome: MACE and MALE

primary safety outcome: major haemorrhage

PRISMA

from inception to date

CENTRAL (?)

MEDLINE

EMBASE

Filtered 5000 results

Bayesian network meta analysis

Presented as forest plots

Vit K antagonists significantly reduce risk of MACE but with significant increased risk of bleed.

This study seemed to be saying that the aspirin - rivaroxaban (presumably 2.5 BD) did not improve patency / MACE MALE